Vitamins in the treatment of chronic viral hepatitis

British Journal of Nutrition

Volumn 105, Issue 7, 2011, Pages 982-989

  Fiorino, Sirio ^a,b   Conti, Fabio ^b   Gramenzi, Annagiulia ^b   Loggi, Elisabetta ^b   Cursaro, Carmela ^b   Di Donato, Roberto ^b   Micco, Lorenzo ^b   Gitto, Stefano ^b   Cuppini, Andrea ^a   Bernardi, Mauro ^b   Andreone, Pietro ^b  

^a Budrio Hospital   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical pharmacology; Inflammation; Liver; Viral hepatitis; Vitamins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ANTIVIRUS AGENT; ASCORBIC ACID; GLUTATHIONE PEROXIDASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; PLACEBO; RETINOIC ACID; RETINOL; SODIUM SELENITE; THIAMINE; VITAMIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; CHRONIC HEPATITIS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; EARDRUM DISEASE; FATIGUE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRIGLYCERIDEMIA; MUCOSAL DRYNESS; MYALGIA; NONHUMAN; REVIEW; SEROCONVERSION; TREATMENT DURATION; VIRUS HEPATITIS; TREATMENT OUTCOME;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; TREATMENT OUTCOME; VITAMINS;

EID: 79955669617     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114510004629     Document Type: Review

References (64)

1. Kane M (1995) Global programme for control of hepatitis B infection. Vaccine 13, S47-S49.
2. Lee WM (1997) Hepatitis B virus infection. N Engl J Med 337, 1733-1745.
3. Di Bisceglie AM (1998) Hepatitis C. Lancet 351, 351-355.
4. European Association for the study of the liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50, 227-242.
5. Delaney WE 4th & Borroto-Esoda K (2008) Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 8, 532-540.
6. Manns MP, McHutchison JG, Gordon SC, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
7. Fried MW, Shiffman ML, Reddy KR, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. (2004) Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140, 346-355.
9. Soriano V, Peters MG & Zeuzem S (2009) New therapies for hepatitis C virus infection. Clin Infect Dis 48, 313-320.
10. Vento S, Cainelli F & Temesgen Z (2008) Perspectives in therapy for hepatitis C. Expert Opin Investig Drugs 17, 1635-1639.
11. Guidotti LG & Chisari FV (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1, 23-61.
12. Bertoletti A & Ferrari C (2003) Kinetics of the immune response during HBV and HCV infection. Hepatology 38, 4-13.
13. Bertoletti A & Gehring AJ (2006) The immune response during hepatitis B virus infection. J Gen Virol 87, 1439-1449.
14. Rehermann B (2007) Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis 27, 152-160.
15. Medina J & Moreno-Otero R (2005) Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 65, 2445-2461.
16. Waris G, Huh KW & Siddiqui A (2001) Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kB via oxidative stress. Mol Cell Biol 22, 7721-7730.
17. Wang HC, Huang W, Lai MD, et al. (2006) Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 97, 683-688.
18. Wang HC, Chang WT, Chang WW, et al. (2005) Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology 41, 761-770.
19. Wang JH, Yun C, Kim S, et al. (2003) Reactive oxygen species modulates the intracellular level of HBx viral oncoprotein. Biochem Biophys Res Commun 310, 32-39.
20. Ghosh AK, Steele R, Meyer K, et al. (1999) Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 80, 1179-1183.
21. Waris G, Tardif KD & Siddiqui A (2002) Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 64, 1425-1430.
22. Gong G, Waris G, Tanveer R, et al. (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappaB. Proc Natl Acad Sci USA 98, 9599-9604.
23. Korenaga M, Okuda M, Otani K, et al. (2005) Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol 39, S162-S166.
24. Piccoli C, Scrima R, Quarato G, et al. (2007) Hepatitis C protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Hepatology 4, 58-65.
25. Farinati F, Cardin R, Bortolami M, et al. (2007) Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat 14, 821-829.
26. Fialkow L, Wang Y & Downey GP (2007) Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 42, 153-164.
27. Okuda M, Li K, Beard MR, et al. (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122, 366-375.
28. Moriya K, Nakagawa K, Santa T, et al. (2001) Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61, 4365-4370.
29. Majano PL, Garc?́a-Monzón C, López-Cabrera M, et al. (1998) Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 101, 1343-1352.
30. Majano P, Lara-Pezzi E, López-Cabrera M, et al. (2001) Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor kappaB-binding site: evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatology 34, 1218-1224.
31. Sprengers D & Janssen HL (2005) Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 19, 17-26.
32. Rocchi E, Casalgrandi G, Ronzoni A, et al. (2001) Antioxidant liposoluble vitamins and carotenoids in chronic hepatitis. Eur J Intern Med 12, 116-121.
33. Maggini S, Wintergerst ES, Beveridge S, et al. (2007) Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 98, S29-S35.
34. Lin CC & Yin MC (2009) Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin. Clin Nutr 28, 34-38.
35. Souza dos Santos RM, de Bem AF, Colpo E, et al. (2008) Plasmatic vitamin C in nontreated hepatitis C patients is negatively associated with aspartate aminotransferase. Liver Int 28, 54-60.
36. Petta S, Cammà C, Scazzone C, et al. (2010) Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51, 1158-1167.
37. Arteh J, Narra S & Nair S (2009) Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 55, 2624-2628.
38. George J, Ganesh HK, Acharya S, et al. (2009) Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 15, 3516-3522.
39. Fisher L & Fisher A (2007) Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 5, 513-520.
40. Grønbaek K, Sonne J, Ring-Larsen H, et al. (2005) Viral load is a negative predictor of antioxidant levels in hepatitis C patients. Scand J Infect Dis 37, 686-689.
41. Van Thiel DH, Friedlander L, Fagiuoli S, et al. (1994) Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 20, 410-415.
42. Bonomi F & Pagani S (1991) Uptake of iron by apoferritin from a ferric dihydrolipoate complex. Eur J Biochem 199, 181-186.
43. Lai CL, Lok AS, Lin HJ, et al. (1987) Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet ii, 877-880.
44. Lai CL, Lin HJ, Lau JN, et al. (1991) Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 78, 155-163.
45. Wallace AE & Weeks WB (2001) Thiamine treatment of chronic hepatitis B infection. Am J Gastroenterol 96, 864-868.
46. Meydani M (1995) Vitamin E. Lancet 345, 170-175.
47. Sies H & Murphy ME (1991) Role of tocopherols in the protection of biological systems against oxidative damage. J Photochem Photobiol B 8, 211-218.
48. Halliwell B & Gutteridge JM (1984) Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet 1, 1396-1397.
49. Andreone P, Fiorino S, Cursaro C, et al. (2001) Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res 49, 75-81.
50. Dikici B, Dagli A, Ucmak H, et al. (2007) Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection. Pediatr Int 49, 603-607.
51. Gerner P, Posselt HG, Krahl A, et al. (2008) Vitamin E treatment for children with chronic hepatitis B: a randomized placebo controlled trial. World J Gastroenterol 14, 7208-7213.
52. Morbitzer M & Herget T (2005) Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. J Biol Chem 280, 8831-8841.
53. Kelner MJ, Bagnell RD, Montoya MA, et al. (2000) Structural organization of the human gastrointestinal glutathione peroxidase (GPX2) promoter and 30-nontranscribed region: transcriptional response to exogenous redox agents. Gene 248, 109-116.
54. Hamamoto S, Fukuda R, Ishimura N, et al. (2003) 9-cis Retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased expression of type I interferon receptor. J Lab Clin Med 141, 58-66.
55. Böcher WO, Wallasch C, Höhler T, et al. (2008) All-trans retinoic acid for treatment of chronic hepatitis C. Liver Int 28, 347-354.
56. von Herbay A, Stahl W, Niederau C, et al. (1997) Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomised, double blind, placebo- controlled study. Free Radic Res 27, 599-605.
57. Look MP, Gerard A, Rao GS, et al. (1999) Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. Antiviral Res 1143, 113-122.
58. Idéo G, Bellobuono A, Tempini S, et al. (1999) Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol 11, 1203-1207.
59. Houglum K, Venkataramani A, Lyche K, et al. (1997) A pilot study of the effects of D-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 113, 1069-1073.
60. Groenbaek K, Friis H, Hansen M, et al. (2006) The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol 18, 985-989.
61. Falasca K, Ucciferri C, Mancino P, et al. (2008) Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J Med Virol 80, 1900-1906.
62. Harrison's (2004) Principles of Internal Medicine, 16th ed., pp. 403-410. New York: McGraw-Hill.
63. Goodman & Gilman's (2001) The Pharmacological Basis of Therapeutics, 10th ed., chapters 63 and 64, pp. 1665-1699. New York: McGraw-Hill.
64. Ghany MG, Strader DB, Thomas DL, et al. (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335-1374.